FELIQS secures $9 million in Series A funding to advance FLQ-101 for retinopathy of prematurity, led by a major American pharma and Beyond Next Ventures.
Amount Raised
$9 Million
Round Type
Series A
KurumeBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
FELIQS Corporation has completed a $9 million Series A funding round, co-led by a major American pharmaceutical company and Beyond Next Ventures. The funding will accelerate the clinical development of FLQ-101 for preventing retinopathy of prematurity. Notable participants include the Japan Science and Technology Agency, and various existing investors. The Phase 1b/2 tROPhy-1 study is set to begin in summer 2025.
Quick answer
FELIQS raised $9 Million in a Series A round, dated July 1, 2025. Investors: Keio Innovation Initiative, Inc., Japan Science And Technology Agency, Mitsubishi UFJ Capital Co., Ltd., Ffg Venture Business Partners Co., Ltd., Keio Innovation Initiative, Major American Pharmaceutical Company and Beyond Next Ventures Inc. FELIQS is based in Kurume, Fukuoka Prefecture, Japan.
- How much did FELIQS raise?
- FELIQS raised $9 Million in a Series A round on July 1, 2025.
- Who invested in FELIQS?
- Keio Innovation Initiative, Inc., Japan Science And Technology Agency, Mitsubishi UFJ Capital Co., Ltd., Ffg Venture Business Partners Co., Ltd., Keio Innovation Initiative, Major American Pharmaceutical Company and Beyond Next Ventures Inc. are named as investors in this round.
- What does FELIQS do?
- FELIQS Corporation is a clinical stage multinational biopharmaceutical company focused on developing first-in-class small molecules to target lipid oxidation.
- Where is FELIQS based and how big is it?
- FELIQS is based in Kurume, Fukuoka Prefecture, Japan. Fundz records about 3 employees.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as FELIQS that raised within 45 days of this round, from Fundz verified event records.
- Faeth Therapeutics raised $24M on August 1, 2025.
- Compugen raised $3.5M (Seed) on July 15, 2025.
- BioSapien raised $8M (Pre-Series A) on July 7, 2025.
- MAIA Biotechnology raised $695K (Seed) on May 28, 2025.
- GRIN Therapeutics raised $140M (Series D) on May 27, 2025.
- Citizen Health raised $30M (Series A) on August 15, 2025.
Who to call at FELIQS, and when
A new round usually means FELIQS is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day FELIQS raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at FELIQS, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at FELIQS. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment FELIQS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansFELIQS raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.